Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT ID: NCT05215340
Last Updated: 2026-01-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
740 participants
INTERVENTIONAL
2022-03-04
2028-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04612751
Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)
NCT04526691
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Eligible participants will be randomized in a 1:1 ratio to the control arm (pembrolizumab alone) or the experimental arm (Dato-DXd and pembrolizumab). The study will be divided into 4 periods: Tissue Screening Period, Screening Period, Treatment Period, and Follow-up Period.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pembrolizumab + Datopotamab Deruxtecan (Dato-DXd)
Participants will be randomized to receive 200 mg pembrolizumab followed by 6.0mg/kg Dato-DXd.
Datopotamab Deruxtecan
Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
Pembrolizumab
Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
Pembrolizumb
Participants will be randomized to receive 200 mg pembrolizumab.
Pembrolizumab
Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Datopotamab Deruxtecan
Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
Pembrolizumab
Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adults ≥18 years or the minimum legal adult age (whichever is greater) at the time of informed consent.
* Histologically documented non-squamous NSCLC that meets all of the following criteria (Note: Subjects with squamous histology were eligible prior to Protocol Version 5.0. After Protocol Version 5.0, subjects with squamous histology are not eligible. Subjects with mixed histology, including those with a squamous component, remain eligible the study even after Protocol Version 5.0):
1. Stage IIIB or IIIC disease and not candidates for surgical resection or definitive chemoradiation, or Stage IV NSCLC disease at the time of randomization (based on the American Joint Committee on Cancer, Eighth Edition). Participants with early-stage NSCLC who have relapsed should be restaged during screening to ensure their eligibility for the study.
2. Documented negative test results for epidermal growth factor receptor (EGFR), lymphoma kinase (ALK), and proto-oncogene1 (ROS1) actionable genomic alterations (AGAs) based on analysis of tumor tissue. If test results for EGFR, ALK, and ROS1 are not available, subjects are required to undergo testing performed locally for these genomic alterations.
3. No known AGAs in neurotrophic tyrosine receptor kinase (NTRK), proto-oncogene B-raf (BRAF), rearranged during transfection (RET), mesenchymal-epithelial transition factor (MET), or other actionable driver kinases with locally approved therapies. (Testing for genomic alterations besides EGFR, ALK, and ROS1 is not required prior to randomization). Subjects whose tumors harbor KRAS mutations are eligible for the study.
* Has provided a formalin-fixed tumor tissue sample for the measurement of trophoblast cell surface protein 2 (TROP2) protein expression and for the assessment of other exploratory biomarkers.
* Tumor has high programmed death receptor-1 (PD-L1) expression (TPS ≥50%) as determined by PD-L1 immunohistochemistry (IHC) 22C3 pharmDx assay by central testing (minimum of 6 slides).
* Has an adequate treatment washout period before Cycle 1 Day 1.
* Measurable disease based on local imaging assessment using RECIST Version 1.1.
* Has left ventricular ejection fraction (LVEF) ≥50% by either an echocardiogram (ECHO) or multigated acquisition scan (MUGA) within 28 days before randomization.
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at screening.
* Has a life expectancy of at least 3 months.
* Adequate bone marrow function within 7 days before randomization.
Exclusion Criteria
* Has received prior treatment for NSCLC with any of the following, including in the adjuvant/neoadjuvant setting:
1. Any agent, including an antibody-drug conjugate, containing a chemotherapeutic agent targeting topoisomerase I.
2. TROP2-targeted therapy.
3. Any anti-programmed death receptor-1 (PD-1), anti-PD-L1, or anti-PD-ligand 2 (L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX40, CD137).
4. Any other immune checkpoint inhibitors. Participants who received adjuvant or neoadjuvant therapy OTHER than those listed above, are eligible if the adjuvant/neoadjuvant therapy was completed at least 6 months prior to the diagnosis of advanced/metastatic disease.
* Has spinal cord compression or active and untreated central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases and who are asymptomatic may participate provided they are radiologically stable.
* Has received prior radiotherapy \< 4 weeks of start of study intervention or more than 30 Gy (unit of ionizing radiation dose in the International System of Units) to the lung within 6 months of Cycle 1 Day 1.
* History of another primary malignancy (beyond NSCLC) except for:
1. Malignancy treated with curative intent and with no known active disease ≥3 years before the first dose of study treatment and of low potential risk for recurrence.
2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
3. Adequately treated carcinoma in situ without evidence of disease.
4. Participants with a history of prostate cancer (tumor/node/metastasis stage) of Stage ≤T2cN0M0 without biochemical recurrence or progression and who in the opinion of the Investigator are not deemed to require active intervention.
* Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis including radiation pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
* Clinically severe pulmonary compromise, as judged by the investigator, resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, or any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement or prior complete pneumonectomy.
* Uncontrolled or significant cardiovascular disease, including:
1. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) interval \>470 ms regardless of sex (based on the average of the 12-lead electrocardiogram determination at screening).
2. Myocardial infarction within 6 months prior to randomization.
3. Uncontrolled angina pectoris within 6 months prior to randomization.
4. LVEF \<50% by ECHO or MUGA scan within 28 days before randomization.
5. New York Heart Association Class 2 to 4 congestive heart failure (CHF) at screening.
6. Uncontrolled hypertension (resting systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg) within 28 days before randomization.
Participants with a history of Class 2 to 4 CHF prior to screening, must have returned to Class 1 CHF and have LVEF ≥50% (by either an ECHO or MUGA scan within 28 days before randomization) in order to be eligible.
* Clinically significant corneal disease.
* Has received a live vaccine or live-attenuated vaccine (messenger ribonucleic acid and replication-incompetent adenoviral vaccines are not considered attenuated live vaccines) within 30 days prior to the first dose of study drug. For any participant receiving an approved severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine, please follow the vaccine label and/or local guidance.
* Active, known, or suspected autoimmune disease (has an active autoimmune disease that has required systemic treatment in the past 2 years).
* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosage \>10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy ≤7 days prior to the first dose of study drug.
* Has known human immunodeficiency virus (HIV) infection that is not well controlled.
* Has an active hepatitis or uncontrolled hepatitis B or active hepatitis C infection.
* Has an uncontrolled infection requiring IV antibiotics, antivirals, or antifungals.
* Had an allogeneic tissue/solid organ transplant.
* Has a history of severe hypersensitivity reactions to either the drug or inactive ingredients (including but not limited to polysorbate 80) of Dato-DXd or pembrolizumab.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
Daiichi Sankyo
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Leader
Role: STUDY_DIRECTOR
Daiichi Sankyo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dokkyo Medical University Hospital
Shimotsuga-gun, Tochigi, Japan
Juntendo University Hospital
Bunkyo-ku, Tokyo, Japan
Ironwood Cancer and Research Center
Chandler, Arizona, United States
UCLA HemOnc - Clinical Research Unit
Los Angeles, California, United States
Compassionate Cancer Care Medical Group
Riverside, California, United States
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
Ridley-Tree Cancer Center
Santa Barbara, California, United States
PIH Health Whittier Hospital
Whittier, California, United States
The Oncology Institute of Hope and Innovation
Whittier, California, United States
Uch-Mhs D/B/A Memorial Health System
Colorado Springs, Colorado, United States
Johns Hopkins University
Baltimore, Maryland, United States
American Oncology Partners of Maryland
Bethesda, Maryland, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
DFCI - Steward St. Elizabeth's Medical Center
Boston, Massachusetts, United States
Dana Farber Cancer Institute - Foxborough
Foxborough, Massachusetts, United States
Dana Farber Cancer Institute - Milford Medical Center
Milford, Massachusetts, United States
DFCI - South Shore Hospital
South Weymouth, Massachusetts, United States
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States
Astera Cancer Care
East Brunswick, New Jersey, United States
Regional Cancer Care Associates LLC
Freehold, New Jersey, United States
Cooperman Barnabas Medical Center
New Brunswick, New Jersey, United States
The Valley Hospital
Paramus, New Jersey, United States
Montefiore Medical Center
The Bronx, New York, United States
Arizona Oncology NAHOA
Irving, Texas, United States
Cancer Care Center of Brevard
Irving, Texas, United States
Illinois Cancer Specialists
Irving, Texas, United States
Maryland Oncology Hematology
Irving, Texas, United States
Southern Cancer Center
Irving, Texas, United States
Texas Oncology - Northeast Texas
Irving, Texas, United States
Texas Oncology Gulf Coast
Irving, Texas, United States
Texas Oncology McAllen
Irving, Texas, United States
Woodlands Medical
Irving, Texas, United States
University of Texas Health Science Center San Antonio
San Antonio, Texas, United States
Utah Cancer Specialists
Salt Lake City, Utah, United States
Providence Regional Cancer System
Lacey, Washington, United States
VA Puget Sound Health Care System - VAPSHCS
Seattle, Washington, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Centro de Investigaciones Medicas y Desarrollo LC S.R.L. (LC Investigacion)
Buenos Aires, , Argentina
Fundacion CENIT para la investigación en Neurociencias
Ciudad Autonoma de Buenos Aire, , Argentina
Hospital Privado de la Comunidad
Mar del Plata, , Argentina
Centro de Investigación Pergamino S. A.
Pergamino, , Argentina
Instituto de Oncología de Rosario
Rosario, , Argentina
Sanatorio Parque
Rosario, , Argentina
Sanatorio Británico de Rosario
Rosario, , Argentina
CER SAN JUAN - Centro Polivalente de Asistencia e Investigación Clínica
San Juan, , Argentina
Clinica Viedma SA
Viedma, , Argentina
Austin Hospital
Heidelberg, Victoria, Australia
Peninsula and South Eastern Haematology and Oncology Group
Mount Waverley, Victoria, Australia
Chris Obrien Lifehouse
Camperdown, , Australia
The Queen Elizabeth Hospital
Woodville South, , Australia
Klinikum Klagenfurt am Wörthersee Abteilung für Lungenkrankheiten
Klagenfurt, , Austria
Karl-Landsteiner Institute for Lung Research and Pulmonary Oncology c/o Klinik Floridsdorf
Vienna, , Austria
Onze-Lieve-Vrouwziekenhuis Olvz - Campus Aalst
Aalst, , Belgium
Grand Hopital de Charleroi - Hopital Saint Joseph
Charleroi, , Belgium
Az Maria Middelares - Campus Maria Middelares
Ghent, , Belgium
AZ Nikolaas
Sint-Niklaas, , Belgium
Instituto de Pesquisas em Saúde - IPS
Caxias do Sul, , Brazil
Hospital Erasto Gaertner
Curitiba, , Brazil
Oncosite - Centro de Pesquisa Clinica Oncologia
Ijuí, , Brazil
Clínica de Neoplasias Litoral
Itajaí, , Brazil
UPCO - Unidade de Pesquisas Clínicas em Oncologia - Clinica Lacks
Pelotas, , Brazil
Santa Casa de Misericordia de Porto Alegre
Porto Alegre, , Brazil
Instituto Nacional de Câncer - INCA
Rio de Janeiro, , Brazil
Centro de Estudos e Pesquisa de Hematologia e Oncologia - CEPHO
Santo André, , Brazil
Instituto de Ensino e Pesquisas Sao Lucas
São Paulo, , Brazil
Instituto do Cancer Brasil - Unidade Taubate
Taubaté, , Brazil
Santa Cabrini Hospital
Montreal, , Canada
McGill University Health Centre
Montreal, , Canada
Centro de Estudios Clínicos SAGA
Santiago, Santiago Metropolitan, Chile
Oncovida
Santiago, , Chile
Fundación Arturo Pérez López
Santiago, , Chile
Orlandi Oncología
Santiago, , Chile
Centro de Investigaciones Clinicas Vina Del Mar
Viña del Mar, , Chile
Guangxi Medical University Affiliated Tumor Hospital
Nanning, Guangxi, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Jilin Cancer Hospital
Changchun, Jilin, China
Sichuan Cancer Hospital
Chengdu, Sichuan, China
Peking University Peoples Hospital
Beijing, , China
Peking University Cancer Hospital
Beijing, , China
Cangzhou People's Hospital
Cangzhou, , China
Hunan Cancer Hospital
Changsha, , China
Army Medical Center of PLA
Chongqing, , China
Affiliated Cancer Hospital and Institute of Guangzhou Medical University
Guangzhou, , China
Haikou People's Hospital
Haikou, , China
The First Affiliated Hospital of College of Medicine Zhejiang University
Hanghzou, , China
Zhejiang Cancer Hospital
Hangzhou, , China
Harbin Medical University Cancer Hospital
Harbin, , China
Inner Mongolia Medical University- the Affiliated Hospital
Hohhot, , China
Jiamusi Tumor and Tuberculosis Hospital
Jiamusi, , China
Yunnan Cancer Hospital
Kunming, , China
Linyi Cancer Hospital
Linyi, , China
The First Affiliated Hospital of Nanchang University
Nanchang, , China
Jiangsu Province Hospital
Nanjing, , China
The Second People's Hospital of Neijiang
Neijiang, , China
Shanghai Pulmonary Hospital
Shanghai, , China
Fudan University Shanghai Cancer Center
Shanghai Shi, , China
The First Hospital of China Medical University
Shenyang, , China
Liaoning Cancer Hospital& Institute
Shenyang, , China
Tianjin Medical University General Hospital
Tianjin, , China
Xinjiang Tumor Hospital
Ürümqi, , China
Union Hospital Affiliated With Tongji Medical College Huazhong University of Science and Technology
Wuhan, , China
Hubei Cancer Hospital
Wuhan, , China
The First Affiliate Hospitalof Xi'An Jiaotong University
Xi'an, , China
The First Affiliated Hospital Xiamen University
Xiamen, , China
Xiangyang Central Hospital- 5 Lumen Avenue
Xiangyang, , China
Sainte-Catherine Institut du Cancer Avignon-Provence (ICAP)
Avignon, , France
Bordeaux University Hospital - Hopital Saint Andre
Bordeaux, , France
Institut Bergonie
Bordeaux, , France
Centre Hospitalier Universitaire de Lille
Lille, , France
Centre Leon Berard
Lyon, , France
APHM - Hopital Nord
Marseille, , France
Institut Paoli-Calmettes
Marseille, , France
Centre Hospitalier Universitaire de Montpellier
Montpellier, , France
CHU de Nantes
Nantes, , France
Hopital prive du Confluent
Nantes, , France
AP-HP - Hopital Tenon
Paris, , France
CHU de Poitier Pole Regional de Cancerologie
Poitiers, , France
Hopital FOCH
Suresnes, , France
Evangelische Lungenklinik Berlin
Berlin, , Germany
Klinikum Esslingen GmbH
Esslingen am Neckar, , Germany
LungenClinic Grosshansdorf
Großhansdorf, , Germany
Klinikum der Universitaet Muenchen
München, , Germany
Metropolitan Hospital
Neo Faliro, Athens, Greece
Sotiria General Hosptial of Chest Diseases
Athens, , Greece
University Hospital of Ioannina Uhi
Ioannina, , Greece
Metropolitan Hospital
Neo Faliro, , Greece
Metropolitan Hospital
Piraeus, , Greece
Bioclinic Thessaloniki
Thessaloniki, , Greece
St. Luke's Hospital
Thessaloniki, , Greece
Prince of Wales Hospital / The Chinese University of Hong Kong 99999
Hong Kong, , Hong Kong
Queen Elizabeth Hospital
Hong Kong, , Hong Kong
Queen Mary Hospital
Pok Fu Lam, , Hong Kong
Semmelweis University Department of Pulmonology
Budapest, , Hungary
Veszprem Megyei Tudogyogyintezet Farkasgyepu
Farkasgyepű, , Hungary
Bkmk Hospital
KecskemĂŠt, , Hungary
Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz
Székesfehérvár, , Hungary
Pulmonology Hospital Torokbalint
Törökbálint, , Hungary
IRCCS Istituto Oncologico Giovanni Paolo II
Bari, , Italy
UOC Oncologia
Chieti, , Italy
Ospedale San Luca
Lucca, , Italy
IRCCS Ospedale San Raffaele
Milan, , Italy
Irccs Istituto Europeo Di Oncologia
Milan, , Italy
Azienda Ospedaliera dei Colli
Naples, , Italy
A.O. Perugia Santa Maria della Misericordia
Perugia, , Italy
Policlinico Tor Vergata
Rome, , Italy
Ifo Regina Elena
Rome, , Italy
Asst Sette Laghi Ospedale di Circolo e Fondazione Macchi
Varese, , Italy
Aomori Prefectural Central Hospital
Aomori, Aomori, Japan
National Cancer Center Hospital East
Kashiwa-shi, Chiba, Japan
NHO Shikoku Cancer Center
Matsuyama, Ehime, Japan
National Hospital Organization Kyushu Cancer Center
Fukuoka, Fukuoka, Japan
Kyushu University Hospital
Fukuoka, Fukuoka, Japan
Kurume University Hospital
Kurume-shi, Fukuoka, Japan
Kanazawa University Hospital
Kanazawa, Ishikawa-ken, Japan
Kanagawa Cancer Center
Yokohama, Kanagawa, Japan
Saiseikai Kumamoto Hospital
Kumamoto, Kumamoto, Japan
Matsusaka Municipal Hospital
Matsusaka-shi, Mie-ken, Japan
Sendai Kousei Hospital
Sendai, Miyagi, Japan
Niigata Cancer Center Hospital
Niigata, Niigata, Japan
Kansai Medical University Hospital
Hirakata-shi, Osaka, Japan
Osaka International Cancer Institute
Osaka, Osaka, Japan
NHO Kinki-Chuo Chest Medical Center
Sakai-shi, Osaka, Japan
Saitama Cancer Center
Ina-machi, Saitama, Japan
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
Bunkyō-Ku, Tokyo, Japan
The Cancer Institute Hospital of JFCR
Kōtoku, Toyko, Japan
Toho University Omori Medical Center
Ōta-ku, Toyko, Japan
NHO Iwakuni Clinical Center
Iwakuni-shi, Yamaguchi, Japan
Yamaguchi-Ube Medical Center
Ube-shi, Yamaguchi, Japan
Yamanashi Prefectural Central Hospital
Kofu, , Japan
University Hospital Kyoto Prefectural University of Medicine
Kyoto, , Japan
Osaka Toneyama Medical Center
Osaka, , Japan
Teine Keijinkai Hospital
Sapporo, , Japan
Cryptex Investigacion Clinica Sa de Cv
Cuauhtémoc, , Mexico
Hospital Civil de Guadalajara Fray Antonio Alcalde
Guadalajara, , Mexico
Hospital Universitario Dr. Jose Eleuterio Gonzalez
Monterrey, , Mexico
Centro de Investigacion Clinica de Oaxaca (CICLO)
Oaxaca City, , Mexico
Oncologico Potosino
San Luis Potosí City, , Mexico
Rijnstate Ziekenhuis
Arnhem, Gelderland, Netherlands
Jeroen Bosch Ziekenhuis J BZ Hieronymus Bosch Hospital
's-Hertogenbosch, , Netherlands
Amsterdam Umc, Location Vumc
Amsterdam, , Netherlands
Leiden University Medical Center
Leiden, , Netherlands
Instytut Centrum Zdrowia Matki Polki
Lodz, Iodzkie, Poland
Szpitale Pomorskie Sp. z o.o.
Gdynia, Pomeranian Voivodeship, Poland
Dom Lekarski SA
Szczecin, West Pomeranian Voivodeship, Poland
II Klinika Chorob Pluc I Gruzlicy
Bialystok, , Poland
MS Pneumed Janusz Milanowski, Katarzyna Szmygin-Milanowska Sp. Jawna
Lublin, , Poland
Centro Clinico Champalimau
Lisbon, , Portugal
Centro Hospitalar e Universitário do Porto
Porto, , Portugal
Hospital CUF Porto
Porto, , Portugal
Instituto Portuguas de Oncologia do Porto Francisco Gentil
Porto, , Portugal
Centro Hospitalar Universitário de São João
Porto, , Portugal
Onco Clinic Consult SA
Craiova, , Romania
Centrul de Oncologie Sf Nectarie S.R.L.
Craiova, , Romania
Sc Sigmedical Services Srl
Suceava, , Romania
Oncocenter-Oncologie Clinica SRL
Timișoara, , Romania
SC Oncomed SRL
Timișoara, , Romania
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Gyeongsang National University Hospital
Jinju, Gyeongsangnam-do, South Korea
Chungbuk National University Hospital
Cheongju-si, North Chungcheong, South Korea
Kyungpook National University Chilgok Hospital
Daegu, , South Korea
National Cancer Center
Goyang-si, , South Korea
Samsung Medical Center
Seoul, , South Korea
The Catholic Univ. of Korea, Seoul St. Mary'S Hospital
Seoul, , South Korea
Asan Medical Center
Songpa-gu, , South Korea
Hospital Clinic i Provincial de Barcelona
Barcelona, , Spain
Hospital Universitari Vall D'Hebron
Barcelona, , Spain
Hospital Universitario Arnau de Vilanova - Lleida
Lleida, , Spain
Hospital General Universitario Gregorio Marañon
Madrid, , Spain
Hospital Clinico San Carlos
Madrid, , Spain
Hospital Universitario Fundacion Jimenez Diaz
Madrid, , Spain
Hospital Regional Universitario Malaga
Málaga, , Spain
CHUO
Ourense, , Spain
Hospital Universitario Virgen Macarena
Seville, , Spain
Hospital Universitario de Valme
Seville, , Spain
Hospital Universitari i Politècnic La Fe
Valencia, , Spain
Hospital Universitario Miguel Servet
Zaragoza, , Spain
Kantonsspital Baden
Baden, , Switzerland
University Hospital Basel
Basel, , Switzerland
Kantonsspital Baselland
Liestal, , Switzerland
Kantonsspital St. Gallen
Sankt Gallen, , Switzerland
E-Da Hospital
Kaohsiung City, , Taiwan
Chang Gung Memorial Hospital Cgmh - Kaohsiung Branch
Kaohsiung City, , Taiwan
Chung Shan Medical University Hospital
Taichung, , Taiwan
Taichung Veterans General Hospital
Taichung, , Taiwan
National Cheng Kung University Hospital Nckuh
Tainan, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
Koo Foundation Sun Yat-Sen Cancer Center
Taipei, , Taiwan
Chang Gung Memorial Hospital LinKou
Taoyuan District, , Taiwan
Srinagarind Hospital
Muaeng, Changwat Khon Kaen, Thailand
Prince of Songkla University PSU - Faculty of Medicine
Hat Yai, Changwat Songkhla, Thailand
Faculty of Medicine Chulalongkorn University
Bangkok, , Thailand
Siriraj Hospital
Bangkok, , Thailand
Adana Acibadem Hospital
Adana, , Turkey (Türkiye)
Akdeniz University Hospital
Antalya, , Turkey (Türkiye)
Ege University
Bornova-İzmir, , Turkey (Türkiye)
Memorial Ankara Hospital Ankara
Çankaya, , Turkey (Türkiye)
Goztepe Prof. Dr. Suleyman Yalcin City Hospital
Istanbul, , Turkey (Türkiye)
Medical Park Seyhan Hospital
Seyhan /Adana, , Turkey (Türkiye)
Birmingham Heartlands Hospital
Birmingham, , United Kingdom
Beatson West of Scotland Cancer Centre
Glasgow, , United Kingdom
Nottingham University Hospitals
Nottingham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
(US Sites) Daiichi Sankyo Contact for Clinical Trial Information
Role: CONTACT
(Asia Sites) Daiichi Sankyo Contact for Clinical Trial Informat
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Levy BP, Felip E, Reck M, Yang JC, Cappuzzo F, Yoneshima Y, Zhou C, Rawat S, Xie J, Basak P, Xu L, Sands J. TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC. Future Oncol. 2023 Jul;19(21):1461-1472. doi: 10.2217/fon-2023-0230. Epub 2023 May 30.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-002555-10
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
KEYNOTE-C73
Identifier Type: OTHER
Identifier Source: secondary_id
MK3475-C73
Identifier Type: OTHER
Identifier Source: secondary_id
2023-507933-12-00
Identifier Type: CTIS
Identifier Source: secondary_id
DS1062-A-U304
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.